Drugs / glutamate
glutamate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00489827 | Oct 2005 → Dec 2009 | coronary artery disorder, myocardial infarction, myocardial ischemia | University Hospital, Linkoeping | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01144039 | Feb 2006 → Nov 2007 | aortic valve stenosis, myocardial ischemia | Medical University of Vienna | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02592824 Comparator | Nov 2015 → Oct 2020 | heart failure, postoperative ventricular dysfunction | University Hospital, Linkoeping | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glutamate | “The main purpose of this study is to determine whether intravenous glutamate infusion given in association with surgery for unstable coronary artery disease can protect the...” NCT00489827 ↗2“Glutamate was administered intravenously immediately after aortic cross-clamp release.” NCT01144039 ↗ |
| Known as | glutamic acid | “Comparisons: Intravenous infusion of 0.125 M glutamic acid solution v saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping...” NCT00489827 ↗ |
| Known as | L-glutamic acid | “Patients were randomly assigned to intravenous infusion of 0.125 M L-glutamic acid or saline (1.65 mL/kg of body weight per hour) intraoperatively and postoperatively.” PMID 32393387 ↗ May 2020 |
| Route | Intravenous | “Patients were randomly assigned to intravenous infusion of 0.125 M L-glutamic acid or saline” PMID 32393387 ↗ May 2020 |